Article

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

2022-11-10

Abstract excerpt

<h4>ABSTRACT</h4> Acute myeloid leukaemia (AML) patients harbouring certain chromosome abnormalities have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular landscape of poor prognosis AML we profiled 74 patients from two different centres (in UK and Finland) at the proteomic, phosphoproteomic and drug response phenot...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 506e0d08-3630-58fb-a322-fcbbfac57e1d
DOI: 10.1101/2022.11.10.515949

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypesDOI 10.1101/2022.11.10.515949Read

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.Semantic proximity Read

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.Semantic proximity Read

Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapiesSemantic proximity Read

Proteomic Characterization of Acute Myeloid Leukemia for Precision MedicineSemantic proximity Read

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Semantic proximity Read

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaSemantic proximity Read

The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.Semantic proximity Read

Lactylation Modulation Identifies Key Biomarkers and Therapeutic Targets in KMT2A- Rearranged AMLSemantic proximity Read

Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis.Semantic proximity Read

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsSemantic proximity Read

Utilizing proteomics and phosphoproteomics to predict <i>ex vivo</i> drug sensitivity across genetically diverse AML patientsSemantic proximity Read

Lactylation modulation identifies key biomarkers and therapeutic targets in KMT2A-rearranged AMLSemantic proximity Read